A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors
Phase: Phase I clinical trials
Principal Investigator: Dott. Duca Matteo
Main Facility: Oncologia Medica 1
Drug: BAY 3713372
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
A first-in-man study with BAY 3713372, an oral protein arginine N-methyltransferase 5 (PRMT5) inhibitor, in adults with MTAP-deleted solid tumors.
The study comprises a dose escalation phase which will evaluate the safety and tolerability of BAY 3713372 administered as monotherapy. Dose escalation will be followed by a cohort expansion phase, evaluating the preliminary anti-tumor activity of BAY 3713372.
Last update: 21/04/2026